Articles by Katie Anderson

  1. 10 Ways To Strengthen U.S. API: Part I 8/29/2025

    Bringing the API supply chain closer to home not only strengthens the supply chain for U.S. drug makers, but it also strengthens the U.S. reserve of critical medicines.

  2. AbbVie Enters Psychedelic Market With Bretisilocin Acquisition 8/28/2025

    Bretisilocin is a next-generation psychedelic compound (5-HT2A receptor agonist and 5-HT releaser) designed to exert a shorter duration of psychoactive experience, while retaining an extended therapeutic benefit

  3. J&J Commits $2 Billion To N.C. Manufacturing Facility 8/21/2025

    J&J’s latest announcement follows its commitment in March to invest $55 billion to support U.S. manufacturing, R&D, and technology over the next four years.

  4. Reimagining Psychedelics: Mental Wellness Without the Roadblocks 8/19/2025

    The rising incidence of mental health disorders brought the mental health benefits of psychedelics back into the spotlight, and we are currently at a watershed moment.

  5. FDA Launches PreCheck Program 8/12/2025

    The program introduces a two-phase approach to enable new U.S. drug manufacturing facilities: The Facility Readiness Phase and the Application Submission Phase.

  6. Gedatolisib Shatters Phase 3 Goals and Scales For Breast Cancer Breakthrough 8/11/2025

    After unprecedented phase 3 clinical trails of gedatolisib, Celcuity is working feverishly with its partners to get the drug ready to offer a new standard of care to those that suffer from advanced breast cancer.

  7. President Trump Demands MFN Prices In Manufacturer Letters 8/7/2025

    President Trump has sent out a letter to 17 major pharmaceutical manufacturers, asking them to commit to lower prices by Sept. 29, 2025, or he plans to deploy every tool in his arsenal to protect American families.

  8. Bristol Myers Squibb Forms Immunology Company With Finance Partner 8/5/2025

    The NewCo pipeline will start with three clinical-stage and two phase 1-ready investigational medicines that each target mechanisms in autoimmune diseases.

  9. George Tidmarsh Named CDER Director 7/24/2025

    Tidmarsh has over 30 years of experience in biotechnology, clinical medicine, and regulatory science and has authored 143 scientific publications and patents.

  10. Sanofi Expands Immunology Portfolio With Blueprint Acquisition 7/24/2025

    Sanofi expanded its portfolio in immunology with the completed acquisition of Blueprint Medicines Corporation.